Menu Search
Equities

Nicox SA

NXOA:STU

Nicox SA

Actions
  • Price (EUR)0.3315
  • Today's Change-0.004 / -1.19%
  • Shares traded0.00
  • 1 Year change-39.40%
  • Beta--
Data delayed at least 15 minutes, as of May 28 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.

  • Revenue in EUR (TTM)3.57m
  • Net income in EUR-17.36m
  • Incorporated1996
  • Employees11.00
  • Location
    Nicox SADrakkar 2 - Batiment D2405 route des DolinesCS 10313 Sophia AntipolisVALBONNE 06560FranceFRA
  • Phone+33 497245300
  • Fax+33 497245399
  • Websitehttp://www.nicox.com
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.